• Genetic TherapyEnrolling

  Study to evaluate SPL84 in adults with cystic fibrosis carrying the 3849 + 10 Kb C->T mutation , protocol number SpliSense SPL84-002

  This study will evaluate the safety, tolerability, effectiveness, and effect on the body of SPL84, an inhaled ASO, in adults with CF carrying the 3849 + 10 Kb C->T mutation.

  • Age:

    18 Years and Older

  • Mutation(s):

    One Copy F508del or No Copies F508del

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    13

  • Length of Participation:

    115 days

• Restore CFTR ProteinEnrolling

  Study of VX-828 in combination with Tezacaftor and Deutivacaftor in healthy participants and in adults with cystic fibrosis. , protocol number Vertex VX23-828-001 Phase 1 Part E

  Part E of this study will look at the safety and tolerability of VX-828 in combination with Tezacaftor and Deutivacaftor in adults with CF. The drug combination is intended to help CFTR function closer to normal. 

  • Age:

    18 Years and Older

  • Mutation(s):

    One Copy F508del

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    12

  • Length of Participation:

    4 months

• Anti-InflammatoryEnrolling

  Study to evaluate BI 1291583 in adults with bronchiectasis , protocol number BI 1397-0014 (Airtivity)

  This study will test the effectiveness, safety, and tolerability of BI 1291583, a drug intended to reduce inflammation in the lungs.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    50 to 100%

  • Number of Visits:

    9

  • Length of Participation:

    76 weeks

• Anti-InfectiveEnrolling

  Study to evaluate two antibiotic treatment approaches for the management of outpatient pulmonary exacerbations in children 3 to 18 years old. , protocol number STOP PEDS 2.0 RCT Main Cohort

  The STOP PEDS study will evaluate the safety and effectiveness of two antibiotic treatment approaches for mild pulmonary exacerbations, which are treated at home, in children with CF.

  • Age:

    3 Years to 18 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    50% or greater

  • Number of Visits:

    6

  • Length of Participation:

    0 days

• ObservationalEnrolling

  An observational study for people with cystic fibrosis ages 6 and older who either changed how they took Trikafta (reduced or altered dose) or stopped taking Trikafta because of new or worsening mental health or cognitive symptoms, and/or liver injury and who plan to switch to Alyftrek. , protocol number RETRIAL

  This observational study will monitor the mental health and liver function of people with cystic fibrosis ages 6 and up who had to stop taking or change how they took Trikafta because of new or worsening mental health/cognitive symptoms (such as depression, anxiety, mood, sleep, and/or brain fog/memory problems) and/or liver symptoms (elevated liver enzymes) , and who plan to start taking Alyftrek.

  • Age:

    6 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    2

  • Length of Participation:

    15 months

• OtherEnrolling

  A study to evaluate the insulin-only Bionic Pancreas in people with cystic fibrosis 14 years of age or older who have cystic fibrosis-related diabetes (CFRD) , protocol number Bionic Pancreas CFRD IOBP V 1.0.

  This study will evaluate the effectiveness and safety of using the insulin-only Bionic Pancreas (BP) system compared to using one’s usual insulin delivery method.

  • Age:

    14 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    4

  • Length of Participation:

    7 months

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.